All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Wavelength-Pharmaceuticals-Insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

InDex Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA

Contact the Supplier

Lead Product(s): Cobitolimod

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 16, 2020

Details:

Company has received positive responses from FDA and EMA regarding phase III development of the company's TLR9 agonist cobitolimod, for the treatment of moderate to severe ulcerative colitis.